Please assess the completion status of the following clinical trial:

Trial Title: Topical IL-1-Ra for Treatment of Posterior Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of posterior blepharitis~* A negative urine pregnancy test result for women of childbearing potential~* Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation~* Normal lid position and closure~* Ability to understand and provide informed consent to participate in this study~* Willingness to follow study instructions and likely to complete all required visits.~Exclusion Criteria:~* History of Stevens-Johnson syndrome or ocular pemphigoid~* History of eyelid surgery~* Intra-ocular surgery or ocular laser surgery within 3 months~* History of microbial keratitis, including herpes~* Active ocular allergies~* Corneal epithelial defect \> 1mm2~* Use of topical steroids or Restasis within the past 2 weeks~* Use of tetracycline compounds (tetracycline, doxycycline, and minocycline) within the last month~* Use of isotretinoin (Accutane) within the past 6 months~* Have had any previous treatment with Anakinra (Kineret®) or any therapeutic agent targeted at IL-1 blockade~* Pregnant or lactating women~* Signs of current infection, including fever and current treatment with antibiotics~* Liver, renal, or hematologic disease~* The use of any other investigational drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm 1 (Type: ACTIVE_COMPARATOR): 2.5% IL-1Ra
- Placebo (Type: PLACEBO_COMPARATOR): Artificial Tear
- Treatment Arm 2 (Type: ACTIVE_COMPARATOR): 5% IL-1Ra

Based on this trial design, predict the completion outcome and termination type (if applicable).